RotateHydrogensLabels

PNX

3,7-DIMETHYL-1-(5-OXOHEXYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE

PNX as a free ligand exists in 4 entries. Examples include: 2A3C 3ARR 3ARU

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name3,7-DIMETHYL-1-(5-OXOHEXYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
Identifiers3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
FormulaC13 H18 N4 O3
Molecular Weight278.31
TypeNON-POLYMER
Isomeric SMILESCC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O
InChIInChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
InChIKeyBYPFEZZEUUWMEJ-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count38
Chiral Atom Count0
Chiral Atomsn/a
Bond Count39
Aromatic Bond Count10
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00806 Different stereochemistry
NamePentoxifylline
Groups
  • approved
  • investigational
DescriptionA methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]
Synonyms
  • Oxpentifylline
  • Pentoxifilina
  • Pentoxifyllin
  • Pentoxifylline
  • Pentoxifyllinum
Brand Names
  • Gapeam Budibac
  • Nu-pentoxifylline-SR 400 mg
  • Pentoxifylline
  • Pentoxifylline SR
  • Ratio-pentoxifylline
Affected OrganismHumans and other mammals
IndicationFor the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
PharmacologyPentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Mechanism of actionPentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist.
Route of administration
  • Oral
  • Topical
Categories
  • Alkaloids
  • Antioxidants
  • Cardiovascular Agents
  • Cardiovascular System
  • Chemical Actions and Uses
ATC-CodeC04AD03
AHFS-Code20:24.00
CAS number6493-05-6

Drug Targets

NameSequence SearchPharmacological ActionActions
Adenosine receptor A2aMPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA...yesantagonist
cAMP-specific 3',5'-cyclic phosphodiesterase 4BMKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL...yesinhibitor
cAMP-specific 3',5'-cyclic phosphodiesterase 4BMKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL...yesinhibitor
Adenosine receptor A1MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVS...yesantagonist
5'-nucleotidaseMCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSK...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682